By Vince Ammoscato, Piramal Pharma Solutions
High-potency active pharmaceutical ingredients (HPAPIs) are a rapidly growing segment of the pharmaceutical industry. This is due to an increased focus on targeted therapeutics in disease areas such as cancer. The global HPAPI market, which includes ADCs (antibody-drug conjugates), is expected to reach nearly $26 billion by 2022.
To take advantage of this fast-growing market, a company must be prepared to safely handle these potent compounds. This includes having the appropriate procedures, controls, and expertise in-house to guarantee the safety of not just the patients who need these drugs but also the employees making them. If these measures are not in place in-house, a company should evaluate potential partners to ensure they possess both the controls and expertise to successfully — and safely — bring its drug to market.